Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.

Monday, April 28, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 28 Crystal Research Associates, LLCannounced today that it has issued an Executive Informational Overview(R)(EIO(R)) on Advaxis, Inc. (OTC Bulletin Board: ADXS). The full 60-page reportcan be found at

Advaxis, Inc. ("Advaxis" or "the Company") uses live, genetically modifiedListeria monocytogenes ("Listeria") to safely create vaccines that stimulatemultiple immune responses against cancer as well as infectious and immunedisorders. Through patented techniques, the Company engineers the Listeriabacteria to secrete a specific antigen. The recipients' immune systemrecognizes and processes that antigen in order to provoke an immune attackagainst the cancer. Advaxis' Listeria platform technology is licensed from theUniversity of Pennsylvania, where it has been developed over the past 15 yearsby Dr. Yvonne Paterson, the scientific founder of the Company and currentchair of its Scientific Advisory Board.

At present, Advaxis is engineering Listeria to fight cervicalintraepithelial neoplasia ("CIN") and cervical, head and neck, prostate,breast, and other cancers. The cancer vaccine market is forecast to reach over$8 billion by 2012, up from $481 million in 2007. In preclinical studies,Listeria-based cancer vaccines have a 100% therapeutic response rate andconsistently provoke tumor regression, completely eliminating tumors in over50% of mice. Moreover, animals dosed with these vaccines show a long-termimmunity against cancer, with new tumor cells unable to grow. This suggeststhat the technology can not only treat existing tumors but may also preventcancer recurrence.

In 2007, Advaxis completed its first human clinical trial of the Listeriaplatform using Lovaxin C, a vaccine for human papillomavirus (HPV)-derivedcervical cancer. In the Phase I trial, the vaccine has been shown to be safelyadministered to humans and well tolerated. To Advaxis' knowledge, it is thefirst entity to safely administer live Listeria as an antigen carrier andimmune system stimulant in humans. A Phase II clinical trial is planned forpatients with CIN I/II in 2008.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm thatprovides institutional-quality, fee-based research to small and mid-capcompanies. Crystal Research Associates' unique and novel product, theExecutive Informational Overview(R) (EIO(R)), is free of investment ratings,target prices, and forward-looking financial models. The EIO(R) presents acrystal clear, detailed report on a company (public or private) in a mannerthat is easily understood by the Wall Street financial community. The EIO(R)details a company's product/technology/service offerings, market size(s), keyintellectual property, leadership, growth strategy, competition, risks,audited financial statements, key events, and other such fundamentalinformation. Crystal Research Associates has offices in New York City andDelray Beach. Crystal Research Associates has been compensated by the Companyin cash of forty thousand U.S. dollars and four hundred thousand four-yearOptions/Warrants to purchase Advaxis' stock for its services in creating thisreport, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operatingresults, potential applications of the Company's technology, opportunities forthe Company, and any other statements about the future expectations, beliefs,goals, plans, or prospects expressed constitute forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of 1995.Any statements that are not statements of historical fact (includingstatements containing the words "will," "believes," "plans," "anticipates,""expects," "estimates," and similar expressions) should also be considered tobe forward-looking statements. There

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store